Clinical trials: Allergic Conjunctivitis
Allergic Conjunctivitis
Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan
Intravenous- injection of beta-1,3-glucan in human is known to induce T helper type 1 response, while oral uptake did not. It was examined whether superfine dispersed beta-1,3-glucan (SDG) contrived to absorbed by intestinal…
- Trial name
- NCT00276445
- Testing
- beta-1,3-glucan
- Where
- Japan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Meiji University of Oriental Medicine
Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis
Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers
The purpose of this study is to evaluate the safety of R89674 0.25% ophthalmic solution in healthy normal volunteers
- Trial name
- NCT00223951
- Testing
- R89674 (generic name not yet established)
- Where
- 6 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Vistakon Pharmaceuticals
Allergic Conjunctivitis
Comparison of Tolerability Between Two Allergy Drops
Comfort is compared between two allergy drops
- Trial name
- NCT01390961
- Testing
- alacaftadine and naphazoline HCl & pheniramine maleate
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hom, Milton M., OD, FAAO
Allergic Rhinitis, Asthma
The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions
Subcutaneous allergen immunotherapy (SCIT) is a widely used and effective treatment modality for allergic rhinoconjunctivitis and asthma.
- Conditions
- Allergic Rhinitis, Asthma, Allergic Conjunctivitis
- Trial name
- SCIT (NCT01878929)
- Testing
- Allergen(Tree, Grass, Weeds)
- Where
- United States
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Allergic Rhinitis, Allergic Conjunctivitis
Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis
This first-in-human (FIH) study is a randomized, double-blinded, placebo-controlled, ascending dose study to investigate the safety, tolerability, and pharmacokinetics of XmAb7195 in adult healthy volunteers and in adult subjects…
- Conditions
- Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis
- Trial name
- NCT02148744
- Testing
- XmAb7195
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Xencor, Inc.
Allergic Conjunctivitis
Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses
The purpose of this study is to assess if BEPREVE (bepotastine besilate ophthalmic solution) 1.5% will have an effect on contact lens wear in patients with contact lens intolerance due to allergic conjunctivitis.
- Trial name
- NCT01337557
- Testing
- Bepotastine
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hom, Milton M., OD, FAAO
Allergic Rhinitis, Conjunctivitis
Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants
Primary objective: To assess the efficacy of a single dose of the anti- Bet v 1 monoclonal antibodies (mAb(s ) in the reduction of allergic nasal symptoms during an out-of-season birch allergen environmental exposure unit (EEU)…
- Trial name
- NCT05430919
- Testing
- REGN5713, REGN5714, REGN5715
- Where
- 3 sites in Canada
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals